Figure 4
From: Suppression of endothelial cell activity by inhibition of TNFα
Certolizumab pegol inhibits HL-60 adhesion to rheumatoid arthritis synovial tissue vessels. Stamper-Woodruff assay and immunofluorescence were performed using frozen rheumatoid arthritis (RA) synovial tissue (ST) sections and fluorescence-labeled human promyelocytic leukemia (HL-60) cells. Synovial vessels are marked by von Willebrand factor antibody in red; calcein AM-labeled HL-60 cells appear as green dots; and cell nuclei are stained blue with 4',6-diamidino-2-phenylindole. HL-60 cells adhere to the synovial vessels (×200) when treated with: (A) mouse-IgG (Ms-Ig; negative control); (B) certolizumab pegol (10 μg/ml); or (C) anti-E-selectin antibody (Ab; positive control). The arrows in (A) to (C) point to HL-60 cells bound to vasculature. The adhesion ratio of each section was determined as the sum of adherent HL-60 cells divided by the sum of blood vessels in up to 10 fields of each section. (D) Adhesion results of the different treatments given as the percentage of Ms-Ig binding, defined as the adhesion ratio of the test group divided by the adhesion ratio of Ms-Ig-treated sections. Results represent the percentage of Ms-Ig binding ± standard error of the mean. n, number of RA patients. *P < 0.05.